Overview

• Kite Pharma, a Gilead unit, agreed to acquire privately held Interius BioTherapeutics for $350 million in cash.
• Interius’ in‑vivo approach delivers DNA by intravenous infusion to program cells inside the patient, aiming to simplify and lower the cost of CAR T therapy.
• The transaction is expected to close pending regulatory approvals, after which Interius will be integrated into Kite’s research team in Philadelphia.
• Gilead said the deal will reduce its 2025 earnings per share by approximately $0.23 to $0.25.
• Investor and clinical interest in in‑vivo CAR T has been rising, with more than $2 billion invested and several programs entering trials, according to Novotech.